Legend Biotech Corporation
LEGN US
LEGN USLegend Biotech Corporation
United States Composite45.65
USD
+1.65
(+3.75%)
Next Earnings
May 13
Held by Insiders
1.29%
Held by Institutions
48.69%
Short % of Float
5.63%
YTD Yield
-28.31%
3Y Yield
56.35%
Company Description
- CEO
- Dr. Ying Huang Ph.D.
- Full Time Employees
- 1,800
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2101 Cottontail Lane Somerset NJ United States 08873
- Website
- www.legendbiotech.com
- Business
- Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.